Sarah Cannon Research Institute’s Post

BioSyngen has achieved a milestone with its pioneering #livercancer treatment, #BST02, receiving Fast Track Designation from #FDA. This designation, marks a pivotal moment in the fight against all types of #liver #cancer, including #hepatocellular #carcinoma and #cholangiocarcinoma. It represents an important step forward for liver cancer treatment, leveraging innovative adoptive #immune #celltherapy technology to offer new possibilities for patients. https://lnkd.in/dDN9R4FB

We’re making significant progress in the fight against #lungcancer. Today at #ASCO24, we shared important results from our Phase 3 clinical trial evaluating treatments for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). After five years of median follow-up, one of our treatments showed unprecedented progression-free survival, with 60% of patients alive without disease worsening.   Lung cancer is the #1 cause of cancer-related death around the world. We have spent years at Pfizer working on developing potential solutions that can help people with cancer live better and longer lives. These results represent Pfizer’s commitment to advancing outcomes for patients.   https://lnkd.in/exjYrybQ

With great pride and joy, I’d like to share a milestone moment we at #Pfizer have experienced in the last 12 hours. At the #ASCO24, we announced groundbreaking results from the 5-year follow up of our Phase 3 CROWN study for ALK+ advanced Non-Small Cell Lung Cancer (NSCLC). The study revealed that 60% of patients achieved 5 years of progression-free survival (PFS) with one of our treatments. In the words of the investigators and Lung Cancer experts, this is unprecedented. As highlighted in the Journal of Clinical Oncology (https://lnkd.in/gw35YHs5), ‘This is the longest PFS ever reported with any single-agent targeted treatment not only in advanced NSCLC but across all metastatic solid tumors’. The significant impact this can have on the quality of life for patients with ALK+ NSCLC and their families is truly humbling. At Pfizer, we are committed to bring breakthrough solutions in oncology and across therapeutic areas to help patients live better and longer lives. Read more at : https://lnkd.in/gJqBNsfW #PFEColleague #CancerResearch #LungCancer #letsoutdocancer 

Compared with the pembrolizumab combination, tiragolumab-based treatment did not show improvements in PFS (HR, 1.27; 95% CI, 1.02-1.57) or OS (HR, 1.33; 95% CI, 1.02-1.73) across the intent-to-treat population. https://lnkd.in/eEFCycyj #NSCLC #cancer #oncology

$MDNA #IL2 Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) The ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one #pancreatic and 70% reduction of target lesion in one #melanoma #cancer patient Dose expansion (monotherapy) study already enrolling with the recommended dose of 90 ug/kg Combo study with $MRK's #Keytruda will start enrolling this quarter! https://lnkd.in/gPPxChdA

The results of a global phase II clinical trial evaluating the efficacy and safety of the combination therapy of Tagrisso (osimertinib) and Tepmetko (tepotinib) in patients with MET-amplified, EGFR-mutant advanced or metastatic non-small cell lung cancer (NSCLC) who progressed after first-line Tagrisso treatment have been published in The Lancet Oncology. This study shows the potential of combination therapy with Tagrisso as a new option after resistance to Tagrisso monotherapy. Additionally, combination therapy with Leclaza is also undergoing clinical trials. For more details, you can read the full study in The Lancet Oncology. https://lnkd.in/g64C3FBU

Early data suggests that bispecific antibody petosemtamab, in conjunction with Keytruda, generates a 60% response rate in patients with second-line head and neck cancer. However, more mature clinical data will give us a clearer picture of how accurate this is. Get in touch to discover how evitria can support your antibody needs. #Biotech #BispecificAntibodies #Antibodies #HeadAndNeckCancer

https://lnkd.in/eWZwNvug. Latest advances in management of stage IV cancer came out of targeted therapy at the Trop-2 receptor in breast cancer after patients failed on hormonal therapy and chemotherapy. Now we have sacituzumab govitecan. See how Dana Farber Cancer Institute research has made a difference in managing HR+/HER2- pts in Tropics-02 clinical trial. FDA approval was in Feb 2023. #breastcancerawarenessmonth #breastcancermanagement #Tropic02trial

The Phase 3 #ECHELON-3 trial reveals that #Adcetris® (brentuximab vedotin), combined with #lenalidomide and #rituximab, significantly improves survival rates for those with relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL) compared to standard care. https://lnkd.in/dypMXVhM

WATCH: Expert oncologists review updates in the treatment of small cell lung cancer that were presented at key conferences in 2022 and discuss data in the context the current treatment landscape. #oncology #lungcancer https://lnkd.in/eBifGffb